ZYUS Life Sciences Corporation (the "Company") , a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, today ...

Nona Biosciences ("Nona" or the "Company"), a global biotechnology company advancing biotherapeutic discovery through innovative technology platforms, today announced the appointment of Dr. Josh Xiao ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of its underwritten offering of $475.0 million aggregate principal amount of 0.50% convertible senior notes due 2032 (the "Notes") ...

"I’m attending so that I can be seen and heard,” said AKF Ambassador Ashli Littleton, who lives in Clarksville, Tennessee and is attending the Kidney Action Summit for the first time. "We have to be ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced its intention to offer, subject to market and other conditions, $400 million aggregate principal amount of convertible senior notes due 2032 ...

Travere Therapeutics TVTX posted a profit for the first quarter on Monday. The company reported quarterly earnings of 5 cents ...

FILSPARI achieved record 993 new PSFs for IgAN in the U.S. in the first quarter; U.S. net product sales grew 88% year over ...

Travere (TVTX) delivered earnings and revenue surprises of -30.74% and -1.84%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

(TVTX) on Monday reported a loss of $37.1 million in its first quarter.

Travere Therapeutics Inc. (NASDAQ:TVTX) reported first quarter results that fell short of Wall Street expectations, with both earnings and revenue missing analyst ...

Population modelling study published in Kidney International ReportsAnalysis of over 1.2 million genomes from five international databases predicts a substantial, previously underdiagnosed adult NPHS2 ...